KLP Kapitalforvaltning AS Invests $521,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

KLP Kapitalforvaltning AS acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM – Free Report ) during the 4th quarter, HoldingsChannel.com reports.

The firm acquired 9,300 shares of the company’s stock, valued at approximately $521,000. A number of other hedge funds and other institutional investors have also bought and sold shares of RYTM. SRS Capital Advisors Inc.



increased its position in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc.

now owns 454 shares of the company’s stock valued at $25,000 after purchasing an additional 400 shares during the period. Raleigh Capital Management Inc. acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $28,000.

SBI Securities Co. Ltd. bought a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $37,000.

R Squared Ltd acquired a new position in Rhythm Pharmaceuticals in the fourth quarter valued at $44,000. Finally, KBC Group NV boosted its position in Rhythm Pharmaceuticals by 78.2% during the fourth quarter.

KBC Group NV now owns 2,251 shares of the company’s stock valued at $126,000 after acquiring an additional 988 shares during the last quarter. Analyst Ratings Changes Several research firms have recently weighed in on RYTM. The Goldman Sachs Group lifted their price objective on Rhythm Pharmaceuticals from $59.

00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a report on Friday, December 20th.

They issued an “outperform” rating and a $76.00 target price for the company. Jefferies Financial Group assumed coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd.

They set a “buy” rating and a $80.00 price target on the stock. Morgan Stanley reiterated an “overweight” rating and set a $72.

00 target price on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Finally, Needham & Company LLC lifted their price target on shares of Rhythm Pharmaceuticals from $64.00 to $66.

00 and gave the company a “buy” rating in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.

com, Rhythm Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $69.46. Rhythm Pharmaceuticals Price Performance RYTM opened at $49.

82 on Friday. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $35.

17 and a fifty-two week high of $68.58. The firm has a market capitalization of $3.

15 billion, a P/E ratio of -11.51 and a beta of 2.32.

The company’s 50-day moving average is $54.79 and its 200 day moving average is $55.08.

Rhythm Pharmaceuticals ( NASDAQ:RYTM – Get Free Report ) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.

69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.

36% and a negative net margin of 230.07%. The firm had revenue of $41.

83 million for the quarter, compared to the consensus estimate of $38.48 million. On average, equities research analysts expect that Rhythm Pharmaceuticals, Inc.

will post -4.32 earnings per share for the current year. Insider Activity In other news, EVP Yann Mazabraud sold 75,000 shares of Rhythm Pharmaceuticals stock in a transaction dated Friday, March 14th.

The shares were sold at an average price of $51.48, for a total value of $3,861,000.00.

Following the completion of the transaction, the executive vice president now owns 40,370 shares in the company, valued at $2,078,247.60. This trade represents a 65.

01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website . Also, insider Joseph Shulman sold 1,281 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th.

The shares were sold at an average price of $59.43, for a total transaction of $76,129.83.

Following the sale, the insider now owns 2,657 shares in the company, valued at $157,905.51. The trade was a 32.

53 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold 108,131 shares of company stock valued at $5,781,098 in the last three months.

Company insiders own 5.60% of the company’s stock. About Rhythm Pharmaceuticals ( Free Report ) Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.

The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. Featured Stories Want to see what other hedge funds are holding RYTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rhythm Pharmaceuticals, Inc.

( NASDAQ:RYTM – Free Report ). Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .

.